Trademarkia Logo

Canada

C$
KELVRI
APPROVED

on 11 Feb 2025

Last Applicant/ Owned by

Teva Pharmaceuticals USA, Inc.

400 Interpace Parkway, Building AParsippany, NJ 07054

US

Serial Number

2006265 filed on 15th Jan 2020

Correspondent Address

OSLER, HOSKIN & HARCOURT LLP

Suite 320, World Exchange Plaza100 Queen StreetOttawa,

ONTARIO

CA

K1P1J9

KELVRI

Trademark usage description

pharmaceutical preparations for the prevention and treatment of alzheimer's disease; pharmaceutical preparations for the prevention and treatment of d Read More

Classification Information


Class [005]
Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely fertility enhancement preparations for human use; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; Cardiovascular pharmaceuticals; Pharmaceutical preparations for treating sensory organ disorders; Pharmaceutical preparations and substances for use in urology; Pharmaceutical preparations for the treatment of neurological disorders, namely, Huntington's disease, cerebral palsy, myasthenia gravia, brain injury, spinal cord injury, seizure disorders.


Classification kind code

11

Mark Details


Serial Number

2006265

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 23
on 3rd Feb 2025
Default Removed
Submitted for opposition 14
on 21st Jan 2025
Default Notice Sent
Submitted for opposition 15
on 21st Jan 2025
Correspondence Created
Submitted for opposition 15
on 25th Jun 2024
Correspondence Created
Submitted for opposition 22
on 17th Jun 2024
Search Recorded
Submitted for opposition 20
on 17th Jun 2024
Examiner's First Report
Submitted for opposition 287
on 10th May 2022
Pre-Assessment Letter Sent
Submitted for opposition 31
on 28th Jan 2020
Formalized
Submitted for opposition 1
on 16th Jan 2020
Created
Submitted for opposition 30
on 15th Jan 2020
Filed